Integration of denosumab therapy in the management of giant cell tumors of bone.

Autor: Miles DT; Department of Orthopaedic Surgery, University of Tennessee College of Medicine Chattanooga, USA., Voskuil RT; Division of Musculoskeletal Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, USA., Dale W; Department of Orthopaedic and Rehabilitation, University of Mississippi School of Medicine, USA., Mayerson JL; Division of Musculoskeletal Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, USA., Scharschmidt TJ; Division of Musculoskeletal Oncology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Nationwide Children's Hospital, USA.
Jazyk: angličtina
Zdroj: Journal of orthopaedics [J Orthop] 2020 Mar 28; Vol. 22, pp. 38-47. Date of Electronic Publication: 2020 Mar 28 (Print Publication: 2020).
DOI: 10.1016/j.jor.2020.03.020
Abstrakt: A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
(© 2020 Professor P K Surendran Memorial Education Foundation. Published by Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: